Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure

Drugs

Volumn 54, Issue 1, 1997, Pages 103-116

  Davis, Rick ^a   Coukell, Allan ^a   McTavish, Donna ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CAPTOPRIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FOSINOPRILAT; LISINOPRIL; NITRATE; PRODRUG; VASODILATOR AGENT;

ANGINA PECTORIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COUGHING; DRUG ACCUMULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; EXERCISE; HEART FAILURE; HEART FUNCTION; HEART INDEX; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART STROKE VOLUME; HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYPOTENSION; INCIDENCE; LIVER METABOLISM; LUNG CAPILLARY PRESSURE; MEAN ARTERIAL PRESSURE; MORTALITY; REVIEW; SURVIVAL; SYMPTOM; URINARY EXCRETION; VERTIGO;

ANGINA; DIGITALIS;

EID: 0030858368     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754010-00012     Document Type: Review

References (53)

1. Murdoch D, McTavish D. Fosinopril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potlential in essential hypertension. Drugs 1992; 43: 123-40
2. Wagstaff AJ, Davis R, McTavish D. Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Drugs 1996 May; 51: 777-91
3. Struthers AD. The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure. Pharmacol Ther 1992; 53: 187-97
4. Kostis JB, Garland WT, Delaney C. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure. Clin Pharmacol Ther 1995 Dec; 58: 660-5
5. Keilani T, Schlueter W, Molteni A, et al. Converting enzyme inhibition with fosinopril does not suppress plasma aldosterone and may not cause hyperkalemia despite moderate renal impairment [abstract]. Clin Res 1991 Oct; 39: 772A
6. Galatius-Jensen S, Wroblewski H, Emmeluth C, et al. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor fosinopril. Cardiovasc Res 1996 Dec; 32: 1148-54
7. Sharma S, Eni J, Gelperin K, et al. The hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Bristol-Myers Squibb, 1995. Report no. CV31,138-05. (Data on file)
8. Sharma S, Eni J, Ilgenfritz J, et al. Sustained haemodynamic improvement following chronic fosinopril therapy in patients with heart failure [abstract no. 1056]. XVIIth Congress of the European Society of Cardiology; 1995 Aug 20-24; Amsterdam
9. Kirpizidis HG, Papazachariou GS. Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients: a double-blind study. Cardiovasc Drugs Ther 1995 Feb; 9: 141-3
10. Oren S, Grossman E, Frohlich ED. Reduction in left ventricular mass in patients with systemic hypertension treated with enalapril, lisinopril, or fosenopril. Am J Cardiol 1996; 77: 93-6
11. Sica DA, Cutler RE, Partner RJ, et al. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet 1991 May; 20: 420-7
12. Keilani T, Schlueler WA, Levin ML, et al. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993 Feb 15; 118: 246-54
13. Maschio G, Cagnoli L, Claroni F, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994; 9: 265-9
14. Corradi L, Lusardi P, Pasolti C, et al. Effects of amlodipine vs fosinopril on microalbuminuria in elderly hypertensive patients with type II diabetes [abstract]. Am J Hypertens 1996 Apr 9; 9(Pt 2): 152
15. Alli C, Lombardo M, Zanni D, et al. Albuminuria and transferrinuria in essential hypertension: effects of antihypertensive therapy. Am J Hypertens 1996 Nov; 9: 1068-76
16. Brown Jr EJ, Chew PH, Maclean A, et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol 1995 Mar 15; 75: 596-600
17. Shettigar U, Hare T, Gelperin K, et al. Efficacy of fosinopril in the treatment of patients with decompensated heart failure. Bristol-Myers Squibb, 1995. Report no. CV31,138-08. (Data on file)
18. Levinson B, Sugerman AA, Couchman T, et al. Advanced age per se has no influence on the kinetics of the active diacid of fosenopril [abstract]. J Clin Pharmacol 1986; 26: 555
19. Hui KK, Duchin KL, Kripalam KJ, et al. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmaeol Ther 1991 Apr; 49: 457-67
20. Singhvi SM, Duchin KL, Morrison RA, et al. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol 1988; 25: 9-15
21. Gehr TWB, Sica DA, Grasela DM, et al. Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Eur J Clin Pharmacol 1991 Aug; 41: 165-9
22. Gehr TWB, Sica DA, Grasela DM, et al. The pharmacokinetics and pharmacodynamics of fusinopril in haemodialysis patients. Eur J Clin Pharmacol 1993; 45 (5): 431-6
23. Greenhaum R, Caspi A, Nouriel H, et al. Comparison of the pharmacokinetics of fosinopril and enalapril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol. In press
24. O'Grady P, Mangold B, Yee K-F, et al. Fosinoprilat and enalaprilat pharmacokinetics in patients with congestive heart failure and renal insufficiency [abstract]. Third International Congress on Heart Failure: 1995 Apr 21-25; Geneva
25. Mangold B, O'Grady P, Yee K-F, et al. Fosinoprilat and lisinopril pharmacokinetics in patients with congestive heart failure and renal insufficiency [abstract]. Third International Congress on Heart Failure; 1995 Apr 21-25; Geneva
26. Zuchelli P, Sclarovsky S, Paz R, et al. Comparison of the pharmacokinetics of fosinoprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Bristol-Myers Squibb, 1997. (Data on file)
27. Ford NF, Lasseter KC, Van Harken DR, et al. Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. J Clin Pharmacol 1995 Feb; 35: 145-50
28. MacLeod CM, Bartley EA, Kripilani KJ, et al. Effect of hepatic function on disposition of fosinopril in humans [abstract]. J Clin Pharmacol 1990; 30: 839
29. Erhardt L, MacLean A, Ilgenfritz J, et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J 1995 Dec; 16: 1892-9
30. Bristol-Myers Squibb. Efficacy and safety of fosinopril versus enalapril in patients with moderate to severe chronic heart failure. 1995. Report no. CV118-014. (Data on file)
31. Bristol-Myers Squibb. Long-term comparison of fosinopril with enalapril administered per os in patients with mild to moderate chronic heart failure. 1995. Report no. CV 118-015/022. (Data on file)
32. Gould AL. A new approach to the analysis of clinical drug trials with withrawals. Biometrics 1980; 36: 721-7
33. Bristol-Myers Squibb. Fosinopril prescribing information. Princeton (NJ), 1996
34. Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother 1996; 30 (1): 55-61
35. Bristol-Myers Squibb. Study report (Protocol CV118-015/ 022). 1995: 208-210 (Data on file)
36. Physicians' Desk Reference 50th ed. Monopril® Bristol-Myers Squibb Co. Medical Economics Company: Montvale (NJ). 1996: 757-760
37. Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995; 16: 741-51
38. American Heart Association heart and stroke facts. Dallas (TX): American Heart Association, 1996
39. Ho KKL, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22 Suppl. A: 6-13A
40. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on angiotensin-converting-enzyme inhibitors in patients with left ventricular dysfunction. Am J Health Syst Pharm 1997 Feb 1; 54: 299-313
41. Thom TJ. Kannel WB. Congestive heart failure: epidemiology and cost of illness. Dis Manage Health Outcomes 1997; 1: 75-83
42. American College of Cardiology/American Heart Association Task Force. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee on evaluation and management of heart failure). J Am Coll Cardiol 1995; 26 (5): 1376-98
43. Kjekshus J. Swedberg K. Treatment of heart failure. J Intern Med 1996 Apr; 239: 335-43
44. Kleber FX, Wensel R. Current guidelines for the treatment of congestive heart failure. Drugs 1996 Jan; 51: 89-98
45. ACE inhibitors in the treatment of heart failure. MeReC Bull 1994 Jan; 5: 1-4
46. Linn WD. Angiotensin-converting enzyme inhibitors in left ventricular dysfunction. Pharmacotherapy 1996; 16 (2 ( Pt 2 )): 50S-8S
47. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-6
48. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991; 325: 303-10
49. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
50. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
51. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35
52. Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practioners? Int J Cardiol 1997; 59: 7-10
53. David D. Jallad N, Germino FW, et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor-associated cough. Am J Ther 1995 Oct; 2: 806-13